Stock DNA
Pharmaceuticals & Biotechnology
CAD 20 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
1.30
-43.41%
1.57
Revenue and Profits:
Net Sales:
10 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-45.0%
0%
-45.0%
6 Months
-41.07%
0%
-41.07%
1 Year
-64.13%
0%
-64.13%
2 Years
-68.27%
0%
-68.27%
3 Years
-84.29%
0%
-84.29%
4 Years
-78.29%
0%
-78.29%
5 Years
-62.5%
0%
-62.5%
Nanalysis Scientific Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
42.67%
EBIT Growth (5y)
-180.89%
EBIT to Interest (avg)
-6.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.99
Sales to Capital Employed (avg)
0.97
Tax Ratio
0.20%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.79
EV to EBIT
-10.88
EV to EBITDA
39.03
EV to Capital Employed
1.34
EV to Sales
0.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-12.35%
ROE (Latest)
-43.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
9.60
11.50
-16.52%
Operating Profit (PBDIT) excl Other Income
-0.80
0.10
-900.00%
Interest
0.40
0.40
Exceptional Items
0.00
-0.40
100.00%
Consolidate Net Profit
-2.10
-2.00
-5.00%
Operating Profit Margin (Excl OI)
-192.30%
-92.30%
-10.00%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -16.52% vs 64.29% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -5.00% vs 51.22% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
45.50
28.50
59.65%
Operating Profit (PBDIT) excl Other Income
1.20
-8.90
113.48%
Interest
1.30
0.30
333.33%
Exceptional Items
-7.60
0.50
-1,620.00%
Consolidate Net Profit
-13.60
-16.80
19.05%
Operating Profit Margin (Excl OI)
-75.70%
-475.50%
39.98%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 59.65% vs 14.92% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 19.05% vs -69.70% in Dec 2023
About Nanalysis Scientific Corp. 
Nanalysis Scientific Corp.
Pharmaceuticals & Biotechnology
Nanalysis Scientific Corp., formerly Canvass Ventures Ltd., is a Canada-based company that is engaged in the business of developing, manufacturing and selling portable nuclear magnetic resonance (NMR) spectrometers for the laboratory instrumentation market. The NMReady-60 is the fully-featured portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The NMReady-60 family of NMR spectrometers are used by chemical professionals in several industries including in oil and gas, chemical, pharma, biotech, food processing and also by the government and university labs.






